Se connecter Inscription gratuite

ProMIS Neurosciences Revenu

Quel est le Revenu de ProMIS Neurosciences?

Le Revenu de ProMIS Neurosciences, Inc. est -CAD$11.78

Quelle est la définition de Revenu?

Le résultat net disponible pour les actionnaires ordinaires correspond au résultat net moins les dividendes privilégiés versés.

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

Revenu des entreprises dans Health Care secteur sur OTC par rapport à ProMIS Neurosciences

Que fait ProMIS Neurosciences?

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Entreprises avec revenu similaire à ProMIS Neurosciences